Seaport Global Securities began coverage on shares of Aldeyra Therapeutics (NASDAQ:ALDX) in a research note released on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $13.00 price objective on the biotechnology company’s stock.
ALDX has been the topic of several other research reports. Zacks Investment Research raised Aldeyra Therapeutics from a sell rating to a buy rating and set a $6.75 price target on the stock in a research note on Tuesday, November 14th. Cantor Fitzgerald started coverage on Aldeyra Therapeutics in a research note on Tuesday, October 24th. They set an overweight rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Aldeyra Therapeutics has an average rating of Buy and a consensus target price of $16.79.
Shares of Aldeyra Therapeutics (NASDAQ ALDX) opened at $7.45 on Friday. The company has a market capitalization of $138.60, a P/E ratio of -5.32 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35. Aldeyra Therapeutics has a 52 week low of $3.80 and a 52 week high of $11.90.
Institutional investors have recently modified their holdings of the stock. Virtu KCG Holdings LLC acquired a new position in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $104,000. Bank of New York Mellon Corp acquired a new position in shares of Aldeyra Therapeutics during the 3rd quarter worth approximately $134,000. Woodstock Corp raised its position in shares of Aldeyra Therapeutics by 20.4% during the 4th quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 9,850 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares during the last quarter. Finally, 683 Capital Management LLC raised its position in shares of Aldeyra Therapeutics by 59.1% during the 3rd quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock worth $6,016,000 after purchasing an additional 310,421 shares during the last quarter. Hedge funds and other institutional investors own 47.89% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.